RecallHawk

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

CHARTWELL RX

Summary

FDA approved EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE by CHARTWELL RX. ANDA (Generic) approval (Not Applicable) on 2023-10-03. TABLET, ORAL.

Details

Source

Drug Approval

External ID

ANDA201802-1

Action Date

2023-10-03

Status

Approved

Category

drug

Product Code

ANDA (Generic)

Product Description

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, TABLET, ORAL. Application: ANDA201802

Context & Analysis

CHARTWELL RX has 64 FDA actions in our database.

Frequently Asked Questions

How often does CHARTWELL RX have FDA actions?

CHARTWELL RX has 64 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "ANDA201802-1" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions